The protocol and current situation of antibiotic and macrolide domains of an international adaptive platform trial “REMAP-CAP”

DOI
  • Koba Shigeru
    Nerima Hikarigaoka Hospital, Department of Critical Care Medicine
  • Nakazono Kenichi
    St. Marianna University Yokohama Seibu Hospital, Department of Pharmacy
  • Saito Hiroki
    University of Toronto, Interdepartmental Division of Critical Care St. Marianna University School of Medicine, Department of Emergency and Critical Medicine
  • Ichihara Naoaki
    St. Marianna University School of Medicine, Department of Emergency and Critical Medicine The Jikei University School of Medicine, Department of Cardiac Surgery
  • Kunishima Hiroyuki
    St. Marianna University School of Medicine, Department of Infectious Diseases
  • Fujitani Shigeki
    St. Marianna University School of Medicine, Department of Emergency and Critical Medicine

Bibliographic Information

Other Title
  • 国際アダプティブ・プラットフォーム試験REMAP-CAPのプロトコルおよび参加の実際：市中肺炎における抗菌薬およびマクロライド系薬投与期間ドメイン

Description

<p>REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia) is an international adaptive platform trial to identify optimal therapeutic management for community-acquired pneumonia including COVID-19. This manuscript describes an overview of REMAP-CAP with particular focus on the antibiotics and macrolide duration domains, both of which are being conducted in Japan.</p><p>In the antibiotic domain, patients with severe community-acquired pneumonia are eligible, and randomized to one of three interventions for initial antibiotic therapy: ceftriaxone plus macrolide, piperacillin tazobactam plus macrolide, or levofloxacin. In the macrolide duration domain, patients randomized to the above two interventions containing macrolide are further randomized to standard (3–5 days) or long-term (14 days) treatment regimen.</p><p>It is anticipated that adaptive platform trials will play a major role in evidence generation for infectious diseases. We hope that researchers in Japan will learn more about an adaptive platform directly through participation in these domains of REMAP-CAP.</p>

Journal

Details 詳細情報について

Report a problem

Back to top